Literature DB >> 34989920

Protective Effects of 18β-Glycyrrhetinic Acid on Neonatal Rats with Hyperoxia Exposure.

Cai Qing1, Liu Ziyun1, Yu Xuefei1, Zhao Xinyi1, Xue Xindong1, Fu Jianhua2.   

Abstract

Bronchopulmonary dysplasia (BPD) is a common devastating pulmonary complication in preterm infants. Supplemental oxygen is a lifesaving therapeutic measure used for premature infants with pulmonary insufficiency. However, oxygen toxicity is a significant trigger for BPD. Oxidative stress disrupts lung development, accompanied by increased pro-inflammatory cytokines and chemokines expression and immune cells infiltration in lung tissue. Licorice, a typical traditional herbal medicine, is commonly used in the medicine and food industries. 18β-Glycyrrhetinic acid (18β-GA), a primary active ingredient of licorice, has powerful anti-oxidative and anti-inflammatory effects. This study aimed to determine whether 18β-GA has a protective effect on neonatal rats with hyperoxia exposure. Newborn Sprague-Dawley rats were kept in either 21% (normoxia) or 80% O2 (hyperoxia) continuously from postnatal day (PN) 1 to 14. 18β-GA was injected intragastrically at 50 or 100 mg/kg body weight once a day from PN 1 to 14. We examined the body weight and alveolar development and measured ROS level and the markers of pulmonary inflammation. Mature-IL-1β and NF-κB pathway proteins, and the NLRP3 inflammasome, were assessed; concurrently, caspase-1 activity was measured. Our results indicated that hyperoxia resulted in alveolar simplification and decreased bodyweight of neonatal rats. Hyperoxia increased ROS level and pulmonary inflammation and activated NF-κB and the NLRP3 inflammasome. 18β-GA treatment inhibited the activation of NF-κB and the NLRP3 inflammasome, decreased ROS level and pulmonary inflammation, improved alveolar development, and increased the bodyweight of neonatal rats with hyperoxia exposure. Our study demonstrates that 18β-GA has a protective effect on neonatal rats with hyperoxia exposure.
© 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Entities:  

Keywords:  18β-Glycyrrhetinic acid; Alveolarization; Bronchopulmonary dysplasia; Inflammation; NF-κB pathway; NLRP3 inflammasome; Reactive oxygen species

Mesh:

Substances:

Year:  2022        PMID: 34989920     DOI: 10.1007/s10753-021-01616-7

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  42 in total

1.  Right ventricular systolic dysfunction in young adults born preterm.

Authors:  Adam J Lewandowski; William M Bradlow; Daniel Augustine; Esther F Davis; Jane Francis; Atul Singhal; Alan Lucas; Stefan Neubauer; Kenny McCormick; Paul Leeson
Journal:  Circulation       Date:  2013-08-13       Impact factor: 29.690

2.  The Evolution of Bronchopulmonary Dysplasia after 50 Years.

Authors:  Steven H Abman; Eduardo Bancalari; Alan Jobe
Journal:  Am J Respir Crit Care Med       Date:  2017-02-15       Impact factor: 21.405

Review 3.  Epidemiology of bronchopulmonary dysplasia.

Authors:  Erik A Jensen; Barbara Schmidt
Journal:  Birth Defects Res A Clin Mol Teratol       Date:  2014-03-17

4.  Cardiovascular risk factors in adolescents born preterm.

Authors:  Marika Sipola-Leppänen; Marja Vääräsmäki; Marjaana Tikanmäki; Petteri Hovi; Satu Miettola; Aimo Ruokonen; Anneli Pouta; Marjo-Riitta Järvelin; Eero Kajantie
Journal:  Pediatrics       Date:  2014-09-01       Impact factor: 7.124

Review 5.  Association of Noninvasive Ventilation Strategies With Mortality and Bronchopulmonary Dysplasia Among Preterm Infants: A Systematic Review and Meta-analysis.

Authors:  Tetsuya Isayama; Hiroko Iwami; Sarah McDonald; Joseph Beyene
Journal:  JAMA       Date:  2016-08-09       Impact factor: 56.272

6.  Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia.

Authors:  Ettore Lignelli; Francesco Palumbo; Despoina Myti; Rory E Morty
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2019-10-09       Impact factor: 5.464

Review 7.  Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment.

Authors:  Jung S Hwang; Virender K Rehan
Journal:  Lung       Date:  2018-01-27       Impact factor: 2.584

8.  Impact of postnatal corticosteroid use on neurodevelopment at 18 to 22 months' adjusted age: effects of dose, timing, and risk of bronchopulmonary dysplasia in extremely low birth weight infants.

Authors:  Deanne Wilson-Costello; Michele C Walsh; John C Langer; Ronnie Guillet; Abbot R Laptook; Barbara J Stoll; Seetha Shankaran; Neil N Finer; Krisa P Van Meurs; William A Engle; Abhik Das
Journal:  Pediatrics       Date:  2009-02-09       Impact factor: 7.124

Review 9.  Bronchopulmonary dysplasia: clinical aspects and preventive and therapeutic strategies.

Authors:  Nicola Principi; Giada Maria Di Pietro; Susanna Esposito
Journal:  J Transl Med       Date:  2018-02-20       Impact factor: 5.531

10.  Impact of pulmonary hypertension on neurodevelopmental outcome in preterm infants with bronchopulmonary dysplasia: a cohort study.

Authors:  H Nakanishi; A Uchiyama; S Kusuda
Journal:  J Perinatol       Date:  2016-07-21       Impact factor: 2.521

View more
  1 in total

Review 1.  Association of immune cell recruitment and BPD development.

Authors:  Motaharehsadat Heydarian; Christian Schulz; Tobias Stoeger; Anne Hilgendorff
Journal:  Mol Cell Pediatr       Date:  2022-08-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.